Pharmidex
Ash Alavijeh is an accomplished Life Science Investment Advisor at A2E INDUSTRIES LIMITED, specializing in deal sourcing, due diligence, investment strategy, and portfolio management since December 2024. In parallel, Ash has served as Head of Operations at Pharmidex since January 2016, overseeing regulatory compliance, IT implementations, and overall operations management. Earlier experience includes roles as a Business Development Analyst and Operations Specialist in various organizations, along with crucial internships in operational and analytical chemistry settings. Educational achievements include an MBA from the University of Hertfordshire and an MSc in Entrepreneurship from UCL, complemented by an MBA Essentials from LSE.
This person is not in any teams
This person is not in any offices
Pharmidex
Pharmidex is an AAALAC-accredited, UK-based CRO founded in 2002. We provide high-quality, cost-effective, flexible and rapid solutions in drug metabolism and pharmacokinetics (DMPK), bioanalysis (non-GLP/GLP/GCP), toxicology (non-GLP/GLP), histology, clinical chemistry, hematology, and in vitro ADME. Pharmidex also offers in silico modelling and efficacy models supporting oncology, CNS, respiratory, stroke, autoimmune, and metabolic disease programs. We work with over 250 global clients, including medical charities, academic groups, biotech, and pharma, and have undertaken over 15,000 studies. In addition to our fee-for-service offering, Pharmidex actively seeks collaboration opportunities in grant-funded projects. To date, we have successfully participated in over 30 collaborative grant-funded projects, partnering with more than 167 global collaborators.